Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-4695

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-4695). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Losartan Potassium 100 mg film-coated tablet label indicating a quantity of 100 tablets. The label includes storage instructions to protect from light and keep out of reach of children, with temperature guidelines (20-25°C, excursions to 15-30°C). It shows the labeler as RemedyRepack Inc., Indiana, PA, and mentions the original manufacturer as Camber Pharma, Inc., Piscataway, NJ. The NDC number 70518-4695-00 is displayed prominently.*

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients up to 16%. Two lines are shown, one dashed for Atenolol and one solid for Losartan Potassium, with a noted adjusted risk reduction of 13% and a p-value of 0.021.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months for Atenolol and Losartan potassium. The graph shows an adjusted risk reduction of 25% with Losartan potassium, p=0.001, indicating lower stroke incidence compared to Atenolol over time.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot chart comparing Losartan Potassium and Atenolol event rates for a primary composite endpoint and fatal/non-fatal stroke across various patient subgroups. The chart displays number of patients, event rates (%) for each drug, and hazard ratios with 95% confidence intervals, stratified by age, gender, race, ISH, diabetes, and history of cardiovascular disease.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium (solid line) and placebo (dashed line). The vertical axis shows the percentage of patients with the event, and the horizontal axis shows time in months. The graph includes a note of a 16.1% risk reduction with Losartan Potassium and a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of Losartan Potassium showing its molecular arrangement, including rings with chlorine, hydroxyl, and potassium ion components as part of the structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.